$ODTX News
Last published 1w ago
- 1w agoODTXOdyssey Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoODTXOdyssey Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireAdditional analyses from the Phase 2a induction period for OD-001 further strengthen clinical proof of concept in ulcerative colitis Completed IND-enabling studies for OD-002, a first-in-class oral SLC15A4 inhibitor
- 3w agoODTXOdyssey Therapeutics Presents Completed Phase 2a OD-001 Induction Results Strengthening Clinical Proof of Concept at UEG Week 2026GlobeNewswireCorrelation between clinical efficacy and changes in inflammatory biomarkers, mucosal transcriptomic signatures, and histologic disease activity strengthens the previously shown clinical proof of concept for OD-001
- 1mo agoODTXOdyssey Therapeutics to Present Design of Phase 2a Study Evaluating OD-001 in Combination with Vedolizumab at ACG 2026GlobeNewswireBOSTON, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (NASDAQ:ODTX) ("Odyssey" or the "Company"), a clinical-stage biopharmaceutical company seeking to transform the standard of care for
- 1mo agoODTXOdyssey Therapeutics to Participate in Stifel 2026 Virtual Immunology and Inflammation ForumGlobeNewswireBOSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (NASDAQ:ODTX) ("Odyssey" or the "Company"), a clinical-stage biopharmaceutical company seeking to transform the standard of care
- 2mo agoODTXOdyssey Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireBOSTON, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (NASDAQ:ODTX) ("Odyssey" or the "Company"), a clinical-stage biopharmaceutical company seeking to transform the standard of care for
- 3mo agoEVOODTXEvotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory DiseasesPR NewswireEvotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced that it has entered a strategic R&D collaboration with Odyssey Therapeutics,...
- 3mo agoODTXOdyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireData from the Phase 2a monotherapy trial of OD-001 accepted for oral presentation at United European Gastroenterology Week in October Phase 2a combination trial of OD-001 with vedolizumab and Phase 2b monotherapy trial
- 4mo agoODTXOdyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireReported positive clinical proof-of-concept data for OD-001, our first-in-class, oral RIPK2 scaffolding inhibitor, in a Phase 2a monotherapy trial for moderate to severe ulcerative colitis Cash on hand as of March 31,
- 6mo agoODTXOdyssey Therapeutics Announces Pricing of Upsized Initial Public OfferingGlobeNewswireBOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. ("Odyssey"), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and